Clinical trial
Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously…
NCT00082134 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00082134 |
|---|---|
| Title | Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel |
| Official title | A Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Every 21 Days in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hormone-refractory Prostate Cancer |
| Intervention type | Drug |
| Interventions | ILX651 |
| Enrollment | 40 |
| Completion | Dec 1, 2005 |
| First posted | May 4, 2004 |
| Last update posted | Mar 5, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: